Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19-CAR-T in Relapsed/Refractory B-Cell Malignancies
NCT06532630Phase 1Recruiting
- Sponsor
- Shanghai First Song Therapeutics
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in B-cell malignancy, sponsored by Shanghai First Song Therapeutics. Primary endpoints: Safety and tolerance at 28 days and Manufacturing feasibility at 1 year. Started Aug 2023; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT06532630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532630.